2014
Effect of time‐of‐flight and point spread function modeling on detectability of myocardial defects in PET
Schaefferkoetter J, Ouyang J, Rakvongthai Y, Nappi C, El Fakhri G. Effect of time‐of‐flight and point spread function modeling on detectability of myocardial defects in PET. Medical Physics 2014, 41: 062502. PMID: 24877836, PMCID: PMC4032408, DOI: 10.1118/1.4875725.Peer-Reviewed Original ResearchConceptsSignal-to-noise ratioDetection signal-to-noise ratioPoint spread functionObserver signal-to-noise ratioEffects of time-of-flightMyocardial defectsHuman observer performanceDefect detectionSlow convergenceTime-of-flight (TOFNon-PSFPostreconstruction smoothingFDG-PET dataTime-of-flightPSF reconstructionCombination of TOFNon-TOFIterationObserver performanceClinical practiceSpread functionReconstruction parametersReconstruction protocolsIterative methodDetection
2013
Monitoring plaque inflammation in atherosclerotic rabbits with an iron oxide (P904) and 18F-FDG using a combined PET/MR scanner
Millon A, Dickson S, Klink A, Izquierdo-Garcia D, Bini J, Lancelot E, Ballet S, Robert P, de Castro J, Corot C, Fayad Z. Monitoring plaque inflammation in atherosclerotic rabbits with an iron oxide (P904) and 18F-FDG using a combined PET/MR scanner. Atherosclerosis 2013, 228: 339-345. PMID: 23582588, PMCID: PMC4128694, DOI: 10.1016/j.atherosclerosis.2013.03.019.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAorta, AbdominalAortic DiseasesAtherosclerosisAtorvastatinContrast MediaDextransDisease Models, AnimalDisease ProgressionFluorodeoxyglucose F18Heptanoic AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsInflammationMagnetic Resonance ImagingMagnetite NanoparticlesPlaque, AtheroscleroticPositron-Emission TomographyPredictive Value of TestsPyrrolesRabbitsRadiographyRadiopharmaceuticalsTime FactorsConceptsFDG-PETPlaque inflammationRegression groupAbdominal aortaAtherosclerotic rabbitsAortic wallMean standard uptake valueStrong FDG uptakeStandard uptake valueContrast-enhanced MRIFDG-PET dataFunctional imaging modalitiesProgression groupBaseline imagingFDG uptakeMR scannerSUVmean valuesUSPIO uptakeAtherosclerotic plaquesMacrophage densityUptake valueEarly changesInflammationRabbit modelDietary changes
2011
P2-09-07: Metabolic Response by FDG-PET in Patients (pts) Receiving Trastuzumab (T) and Lapatinib (L) for HER2+ Metastatic Breast Cancer (MBC): Correlative Analysis of TBCRC 003.
Yap J, Locascio T, Najita J, Mayer I, Hobday T, Falkson C, Dees E, Gelman R, Rimawi M, Nanda R, Berkowitz J, Franchetti Y, Wolff A, Winer E, Lin N, Van den Abbeele A. P2-09-07: Metabolic Response by FDG-PET in Patients (pts) Receiving Trastuzumab (T) and Lapatinib (L) for HER2+ Metastatic Breast Cancer (MBC): Correlative Analysis of TBCRC 003. Cancer Research 2011, 71: p2-09-07-p2-09-07. DOI: 10.1158/0008-5472.sabcs11-p2-09-07.Peer-Reviewed Original ResearchMedian progression-free survivalProgression-free survivalMetastatic breast cancerClinical benefitCohort 2Cohort 1FDG-PETWk 8Objective responsePrior linesClinical outcomesMetabolic responseTarget lesionsWk 1Longer progression-free survivalMaximum standardized uptake valuePhase II trialFDG-PET studiesStandardized uptake valueFDG-PET dataFDG-PET imagesEORTC criteriaHypermetabolic uptakeRECIST 1.0II trial
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply